AGP
EW icon

Aspire Growth Partners’s Edwards Lifesciences EW Stock Holding History

Aspire Growth Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,137
Closed -$267K – 122
2025
Q4 		$267K Sell
3,137
-19
-0.6% -$1.56K 0.19% 101
2025
Q3 		$245K Buy
3,156
+49
+2% +$3.83K 0.18% 104
2025
Q2 		$243K Sell
3,107
-64
-2% -$4.77K 0.2% 101
2025
Q1 		$238K Sell
3,171
-28
-0.9% -$2K 0.21% 101
2024
Q4 		$237K Buy
+3,199
New +$224K 0.23% 90

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Aspire Growth Partners's EW Position: Q1 2026 in Review

Aspire Growth Partners sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 3,137 shares — an estimated $267K sold.

Aspire Growth Partners first reported a position in EW in Q4 2024 and held it in 5 quarters. The position peaked at $267K in Q4 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Aspire Growth Partners reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • Aspire Growth Partners sold 3,137 Edwards Lifesciences shares in Q1 2026, an estimated $267K.
  • Aspire Growth Partners first reported a position in Edwards Lifesciences in Q4 2024 and held it in 5 quarters.
  • Aspire Growth Partners's Edwards Lifesciences position peaked at $267K in Q4 2025.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Aspire Growth Partners's 13F filing for Q1 2026, filed 17 Apr 2026.